| ID | 119063 |
| 著者 |
Hatakeyama, S
Sakamoto Hospital
Okada, M
Sakamoto Hospital
Iwatsuki, N
Sakamoto Hospital
Ogawa, T
Sakamoto Hospital
Sakamoto, K
Sakamoto Hospital
|
| キーワード | imeglimin (Twymeeg)
COVID-19
gastrointestinal adverse effects (GIAEs)
Trials of IMeglimin for Efficacy and Safety (TIMES) 2
Hospital Anxiety and Depression scale (HADS)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: For oral hypoglycemic agent (OHA), imeglimin (Twymeeg) has been in focus.
Case presentation: The patient is 83-year-old female with type 2 diabetes (T2D). She skipped visiting clinic and taking HOAs for several months due to COVID-19 prevalence in the society. Result: She was hospitalized with HbA1c 10.3%. Combined treatment of Twymeeg 2000mg/day and linagliptin was initiated, and HbA1c decreased to 6.9% in 12 weeks. She felt no gastrointestoinal adverse effects (GIAEs). Discussion and conclusion: Trials of IMeglimin for Efficacy and Safety (TIMES) 2 and 3 showed clinical efficacy of combined treatments. This elderly case had satisfactory clinical effect. |
| 掲載誌名 |
International Journal of Endocrinology and Diabetes
|
| ISSN | 26943875
|
| 出版者 | Pubtexto Publishers
|
| 巻 | 5
|
| 号 | 3
|
| 開始ページ | 142
|
| 発行日 | 2022-09-12
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
